國際醫學(000516.SZ)：擬7.8億元出售漢氏聯合3400萬股股份
格隆匯 11 月 17日丨國際醫學(000516.SZ)公佈，2020年11月17日，公司全資子公司西安國際醫學中心有限公司(“醫學中心”)與濟南銀豐格物長盈醫療科技合夥企業(有限合夥)(“濟南銀豐”)簽訂了《附條件生效的股份轉讓合同》，擬將醫學中心持有的北京漢氏聯合生物技術股份有限公司(“漢氏聯合”)全部3400萬股股份(佔漢氏聯合全部股份的31.36%)，以7.8億元的價格出售給濟南銀豐。
漢氏聯合成立於2007年1月8日；註冊資本為人民幣10,842.8995萬元；統一社會信用代碼：911103027975666680；法定代表人為韓忠朝；住所為北京市北京經濟技術開發區康定街1號院3號樓一、二層；經營範圍為細胞工程、細胞系列技術工程、細胞治療、細胞抗體、細胞醫藥、基因藥物、保健品、化粧品、診斷試劑、醫療器械的技術開發、技術服務、技術諮詢、技術轉讓、技術檢測；銷售化粧品(未經專項審批的項目除外)、辦公用品、電子設備、儀器儀表、汽車、化工產品；投資管理；技術進出口、貨物進出口；批發藥品；零售藥品。
根據公司的發展戰略和投資計劃，公司近年來不斷整合現有投資項目，盤活存量資產，取得了較好的投資收益，目前，公司正在穩步推進醫療服務主業的發展步伐，西安高新醫院、西安國際醫學中心醫院穩健發展，西安高新醫院二期擴建、商洛國際醫學中心醫院新院區、西安國際康復醫學中心醫院將陸續投入運營，公司醫療服務業務資金需求有所增加，此次將所持漢氏聯合全部股份予以轉讓出售，可以收回投資資金，並實現良好的投資收益，將為公司大力發展醫療服務業務提供資金支持，促進公司的良性運行和可持續發展。此次股份轉讓完成後，公司不再持有漢氏聯合股份。
濟南銀豐的執行事務合夥人為銀豐醫療，其公司經營穩定，信譽良好，濟南銀豐認繳出資足以支付本次股份轉讓款，公司收回股份轉讓款的或有風險很低。
此次擬出售持有的漢氏聯合3400萬股股份，交易金額為7.8億元，預計可實現投資收益約7.21億元，達到較好的投資增值目的，將對公司的財務狀況和經營成果產生積極的影響。公司將依託自身資源優勢，繼續致力於推動幹細胞等現代生物技術臨牀轉化及應用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
